reports
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Compa...
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the gr...
AEON Biopharma Receives Additional Notice Related to NYSE American Con...
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that, following its year-end financial results, the Company is not in compliance with an additio...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 67,...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date an...
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equi...
Arhaus Expands in Northern Virginia with New Ashburn Showroom
Arhaus Expands in Northern Virginia with New Ashburn Showroom The artisan-crafted furnishings brand deepens its roots in Northern Virginia with a new showroom opening at One Loudoun BOSTON HEIGHTS, Ohio, April 03, 2026 (GLOBE NEWSWIRE) -- , Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a premium home furnishings brand known for responsibly sourced, artisan-crafted products and heirloom-quality design, today announced the opening of its new approximately 19,300-square-foot showroom in Ashburn, Virginia. Located within the One Loudoun, the new showroom marks Arhaus’ fifth location in ...
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 11,800 shares of its common stock. The awards were approved by the Compensation Committee of the Company’s Board of Directors and were granted outside of ...
First Hawaiian to Report First Quarter 2026 Financial Results on April...
First Hawaiian to Report First Quarter 2026 Financial Results on April 24, 2026 HONOLULU, April 03, 2026 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its first quarter 2026 financial results on Friday, April 24, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time). To access the call by phone, participants will need to click on the following registration link: , register for the conference call, and then you will receive...
NPK International Inc: 1 director
A director at NPK International Inc sold 35,000 shares at 14.510USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Vale S.A.: 2 directors
Two Directors at Vale S.A. bought 23,454 shares at 16.112USD. The significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Ciena Corp: 2 directors
Two Directors at Ciena Corp sold 4,964 shares at between 401.710USD and 415.512USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
RCM Technologies, Inc. Announces Fourth Quarter And Fiscal Year 2025 R...
RCM Technologies, Inc. Announces Fourth Quarter And Fiscal Year 2025 Results PENNSAUKEN, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty healthcare, and information technology services, today announced financial results for the fourteen and fifty-three weeks ended January 3, 2026. RCM Technologies reported revenue of $86.5 million for the fourteen weeks ended January 3, 2026 (the current quarter), an i...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.